Among them, APL (anticardiolipin (CL), anti-β2-glycoprotein 1 (anti-β2GP1) and lupus anticoagulant)have been extensively studied, with different reports detecting them in 20-30% of patients with SLE. This evidence concerns the gene APOH and acute promyelocytic leukemia.